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summary
Pain, a complex phenomenon influenced by a series of genetic, biological, psychological and social factors, is 
a major component of many rheumatological conditions and the result of physiological interactions between 
central and peripheral nervous system signalling (1, 2). It may be acute or chronic (generally defined as lasting 
≥ three months): acute pain is often primarily attributable to inflammation and/or damage to peripheral struc-
tures (i.e. nociceptive input), whereas chronic pain is more likely to be due to input from the central nervous 
system (CNS) (2, 3).
The many different aspects of pain mean that rheumatologists and other clinicians need to have enough ex-
pertise to diagnose the type of pain correctly and treat it appropriately (3, 4). However, most rheumatologists 
receive little formal training concerning contemporary theories of pain processing or management, and this may 
affect the clinical results of any specific target therapy.
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n	 TYPES OF PAIN
Rheumatological syndromes are gener-ally chronic and this is often reflected 
in the onset and persistence of symptoms 
such as pain, whose physiopathological 
characteristics may change over time. For 
example, the pain associated with rheuma-
toid arthritis (RA) is probably nociceptive 
in origin when the joints are inflamed, but 
may gradually become centralised as it 
spreads throughout the body, which means 
it may also be simultaneously nociceptive 
and centralised for long periods of time (4, 
5). Consequently, it may be necessary to 
treat (or prevent) the centralised aspects 
of pain while providing anti-nociceptive 
treatment.
n	 THE ROLE OF CENTRALISED  
 PAIN IN CLASSIC RHEUMATIC  
 DISEASES
It has been known for some time that as 
many as 15-30% of patients with classic 
autoimmune or rheumatic disorders also 
have a co-morbid fibromyalgia (FM), once 
known as “secondary FM” (4). As these 
rates are much higher than the prevalence 
of FM in the general population (2%), it 
seems that the pain and/or stress accom-
panying chronic rheumatic diseases is also 
capable of triggering conditions such as 
FM (2). 
It has been shown that subsets of patients 
with any chronic pain condition are char-
acterised by female gender, early life trau-
ma, a personal or family history of chronic 
pain, or a personal history of other central-
ly mediated symptoms (insomnia, fatigue, 
memory problems and mood disturbances) 
and cognitions such as catastrophising, and 
that all of these factors can predict the like-
lihood that acute pain will become chronic 
(6, 7). 
Immunological cascades may play a role in 
maintaining central sensitivity and chronic 
pain, which is increased when CNS glial 
cells release pro-inflammatory cytokines; 
the traditional dichotomy of inflamma-
tory vs non-inflammatory pain may there-
fore be less appropriate than previously 
thought (6). 
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n	 MULTIFOCAL PAIN  
 AND ANCILLARY SYMPTOMS
One of the simplest means of identifying 
subjects whose chronic pain has become 
centralised is to look for the symptoms of 
co-morbidities (1, 8). The occurrence of 
multifocal pain in conjunction with other 
centrally mediated symptoms is frequently 
observed in patients developing centralised 
pain (8, 9). The leading pathophysiologi-
cal theory concerning concomitant clusters 
of somatic symptoms and higher than ex-
pected rates of mood disorders is that the 
abnormal centrally acting neurotransmit-
ters that probably play a role in causing 
pain (e.g. low levels of norepinephrine, 
GABA or serotonin, and high levels of glu-
tamate or substance P) are also involved 
in controlling sleep, mood and alertness 
(8). The best support for this hypothesis 
is that when centrally acting analgesics 
such as selective serotonin and norepi-
nephrine re-uptake inhibitors (SSNRIs), 
gabapentinoids, tricyclic antidepressant or 
g-hydroxybutyrate are effective in relieving 
chronic pain, this is frequently accompa-
nied by improvements in other symptom 
domains (1, 10-12).
n	 IS PAIN THE SAME  
 IN DIFFERENT RHEUMATIC  
 CONDITIONS?
Identifying subsets of patients affected by 
different rheumatic or autoimmune dis-
eases with prominent CNS factors might 
also help to explain a long-standing co-
nundrum (10). Peripherally based models 
clearly cannot explain much of the vari-
ance in pain, fatigue, sleep, memory prob-
lems and functional disability that is not 
accounted for by peripheral factors alone. 
For example, although the pathological fo-
cus in osteoarthritis (OA) is the joint and 
surrounding structures, patients with knee 
OA frequently experience multifocal pain 
in areas unaffected by OA (4, 5). Similarly, 
there are other somatic symptoms that can-
not be explained on the basis of a purely 
peripheral condition: studies have found 
that fatigue is a major problem in patients 
with knee OA as many of them find it a 
more functionally limiting symptom than 
pain (5, 8). Peripherally based theories of 
the pathogenesis of OA, systemic lupsu 
erythematosus (SLE), and inflammatory 
arthritis simply do not explain why these 
other symptoms are so common and often 
refractory to standard therapies (1, 5).
n	 THE COMPLEXITY  
 OF TREATMENT
Pain can be most effectively treated by 
carefully selecting various pharmacologi-
cal and non-pharmacological interven-
tions based on the characteristics of the 
pain itself, disease factors, psychological 
coping abilities, and lifestyle factors (11). 
Inadequately treated chronic pain prevents 
many patients from taking part in everyday 
activities, adversely affects their working 
abilities, and contributes to a high rate of 
depression and anxiety. The chronic non-
cancer pain associated with rheumatic 
diseases is often inadequately managed 
(10). Paracetamol and non-steroidal anti-
inflammatory drugs (NSAIDs) are still 
used to treat of chronic rheumatic diseases, 
but there is increasing evidence that tradi-
tional non-selective NSAIDs and selective 
cyclooxygenase 2 inhibitors can have toxic 
effects (11-13). This is particularly impor-
tant in the case of elderly patients, who are 
more likely to have significant problems 
with pain than their younger counterparts, 
and are at high risk of NSAID-related ad-
verse events. If paracetamol and other non-
opioid analgesics are ineffective, it may be 
more appropriate to administer mild opi-
oids (codeine or tramadol) or even strong 
opioids, such as morphine, hydromorphone 
and oxycodone (13). Adequate pain relief 
requires an understanding of individual 
needs, and it has been found that non-phar-
macological techniques such as cognitive 
behavioural therapy, biofeedback, medita-
tion and mindfulness training, and relax-
ation therapy can all help patients suffering 
from rheumatic pain (11, 14, 15). Further-
more, almost any form of physical activ-
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ity is essential for the global health in all 
patients with musculoskeletal complaints, 
and exercise has many beneficial effects on 
the physical and mental status of patients 
with chronic pain (14).
n	 CONCLUSIONS
Chronic pain does not have the same rel-
evance in all rheumatic or autoimmune dis-
eases, and it is still unknown why pain re-
mains localised to a specific joint or topo-
graphical area in some patients, but spreads 
throughout the body in others (16). Some 
risk factors clearly play a major role in the 
clinical expression of pain and related syn-
dromes, including genetics, age, gender, 
co-morbidities, traumas and psychological 
patterns, but there no specific clinical, lab-
oratory or neuroimaging markers that can 
indicate why and when a patient’s localised 
pain will evolve into chronic widespread 
pain. Nevertheless, it is clear that the in-
tensity and localisation of pain should be 
assessed during any clinical evaluation, 
and that pain of any type must always be 
treated in order to prevent it from becom-
ing chronic. Finally, the treatment itself 
should be based on an integrated therapeu-
tic strategy that goes beyond specific dis-
ease-related therapy, and takes into account 
the peripheral pattern and centralisation of 
pain in each individual patient, and the psy-
chosocial factors affecting the response to 
pain (17). Pain may become less of a prob-
lem if we do our best to treat it promptly 
and appropriately. 
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